Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.88 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.88 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | FABP3 | P05413 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | PTAFR | P25105 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159882 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL15709161 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL234634 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL23188433 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL235532 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL25354838 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL416515 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL45162 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL22492184 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL1649042 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2026-05-28 | — | — | US | claimed |
| EP-4743094-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | Eden Ophthalmic Pte Ltd. (SG) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| US-20260077108-A1 | Medicament-Coated Balloon Coating Solution, Coating Material, Medicament-Coated Balloon, Preparation Method Therefor, and Use Thereof | CARDIO NAVI MEDTECH WUHAN CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4306104-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRUS INFECTIONS, COMPRISING POLYMER NANODISCS | MVRIX CO LTD (KR) | 2026-03-18 | — | — | EP | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| EP-4637983-A1 | METHOD FOR PROVIDING A LIPOSOME SOLUTION FOR FORMATION OF MICROVESICLES | DEMCON CURONIX B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-4626400-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4606396-A1 | MEDICAMENT-COATED BALLOON COATING SOLUTION, COATING MATERIAL, MEDICAMENT-COATED BALLOON, PREPARATION METHOD THEREFOR, AND USE THEREOF | Cardio Navi MedTech (Wuhan) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| US-20080118489-A1 | Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-22 | — | — | US | claimed |
| EP-0971699-A4 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-6306432-B1 | FOR CONTROLLING THE RELEASE RATE FROM HIGH DRUG LOAD FORMULATIONS | CHIRON CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-6241999-B1 | SUBSTITUTING FIRST AMPHIPATHIC LIPID WITH ONE HAVING A SIMILIAR STRUCTURE BUT MORE C ATOMS | SKYEPHARMA, INC. | 2001-06-05 | — | — | US | claimed |
| US-6193998-B1 | INCREASING EFFICIENCY USING MULTIVESICULAR LIPOSOMES CONTAINING PHOSPHOLIPIDS | SKYEPHARMA INC. | 2001-02-27 | — | — | US | claimed |
| US-6171613-B1 | REPLACING AMPHIPATHIC LIPIDS | SKYEPHARMA INC. | 2001-01-09 | — | — | US | claimed |
| EP-0971699-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SkyePharma Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| US-5997899-A | INCREASING THE NUMBER OF CARBONS IN THE CARBON CHAIN OF AT LEAST ONE LIPID IN THE LIPID COMPONENT OF THE LIPOSOME, WHEREIN THE CHEMICAL STRUCTURES OF THE TWO LIPIDS ARE OTHERWISE SUBSTANTIALLY SIMILAR. | SKYEPHARMA INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998033483-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA, INC. (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | SMN1; SMN2 1229/4885NR5A2 2880/4885NR5A1 1758/4885 |
| US-20260077108-A1 | Medicament-Coated Balloon Coating Solution, Coating Material, Medicament-Coated Balloon, Preparation Method Therefor, and Use Thereof | LIPA, CETP, NPC1L1 | SMN1; SMN2 2809/4885NR5A2 3932/4885NR5A1 2121/4885 |
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | STARD3, STARD7, PHOSPHO1 | SMN1; SMN2 3764/4885NR5A2 912/4885NR5A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.